The immune response in inflammatory bowel disease (Q36846736)

16 August 2017

1 reference

title

The immune response in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

16 August 2017

0 references

inflammation

0 references

author name string

Steven J Brown

series ordinal

1

1 reference

PubMed ID

17561966

16 August 2017

Lloyd Mayer

series ordinal

2

1 reference

PubMed ID

17561966

16 August 2017

language of work or name

English

0 references

publication date

11 June 2007

1 reference

The American Journal of Gastroenterology

16 August 2017

1 reference

16 August 2017

102

1 reference

16 August 2017

9

1 reference

16 August 2017

2058-2069

1 reference

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

16 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Increased expression of interleukin 17 in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Evidence for function of Ia molecules on gut epithelial cells in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Diversification, expression, and gamma delta T cell recognition of evolutionarily distant members of the MIC family of major histocompatibility complex class I-related molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Regulation of chronic colitis in athymic nu/nu (nude) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Activation of a unique population of CD8(+) T cells by intestinal epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Genetics of inflammatory bowel disease: scientific and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Modulation of epithelial cell growth by intraepithelial gamma delta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Strategies for targeting tumour necrosis factor in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Inflammatory bowel disease: etiology and pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Bacterial flagellin is a dominant antigen in Crohn disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Ectopic CD40 ligand expression on B cells triggers intestinal inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Colonic bacteria express an ulcerative colitis pANCA-related protein epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Identification of a novel bacterial sequence associated with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

The immunological and genetic basis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

New concepts in the pathophysiology of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Interleukin-10-deficient mice develop chronic enterocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Altered immune system glycosylation causes colitis in alpha1,2-fucosyltransferase transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Analysis of the Foxp3/scurfin gene in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

The immunology of mucosal models of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Crohn's fistula: current concepts in management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Review article: antibiotics and probiotics in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Antimicrobials in the management of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Infections and anti–tumor necrosis factor α therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Sargramostim for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01343.X

10.1111/J.1572-0241.2007.01343.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17561966